Trust Company of Vermont’s Esperion Therapeutics ESPR Stock Holding History

Trust Company of Vermont’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-300	Closed	-$295	–	1124
2025 Q2	$295	Hold	300	–	–	﹤0.01%	1055
2025 Q1	$432	Hold	300	–	–	﹤0.01%	994
2024 Q4	$660	Hold	300	–	–	﹤0.01%	1005
2024 Q3	$495	Hold	300	–	–	﹤0.01%	1003
2024 Q2	$666	Hold	300	–	–	﹤0.01%	848
2024 Q1	$804	Buy	+300	New	+$729	﹤0.01%	808
2023 Q4	–	Sell	-300	Closed	-$294	–	829
2023 Q3	$294	Hold	300	–	–	﹤0.01%	787
2023 Q2	$417	Hold	300	–	–	﹤0.01%	798
2023 Q1	$477	Hold	300	–	–	﹤0.01%	843
2022 Q4	$1.87K	Hold	300	–	–	﹤0.01%	814
2022 Q3	$2K	Hold	300	–	–	﹤0.01%	919
2022 Q2	$2K	Buy	+300	New	+$1.7K	﹤0.01%	857
2022 Q1	–	Sell	-300	Closed	-$2K	–	442
2021 Q4	$2K	Buy	+300	New	+$2.4K	﹤0.01%	770
2021 Q3	–	Sell	-300	Closed	-$6K	–	432
2021 Q2	$6K	Hold	300	–	–	﹤0.01%	678
2021 Q1	$8K	Hold	300	–	–	﹤0.01%	649
2020 Q4	$8K	Hold	300	–	–	﹤0.01%	650
2020 Q3	$11K	Hold	300	–	–	﹤0.01%	596
2020 Q2	$15K	Hold	300	–	–	﹤0.01%	568
2020 Q1	$9K	Hold	300	–	–	﹤0.01%	669
2019 Q4	$18K	Hold	300	–	–	﹤0.01%	622
2019 Q3	$11K	Hold	300	–	–	﹤0.01%	730
2019 Q2	$14K	Hold	300	–	–	﹤0.01%	690
2019 Q1	$12K	Hold	300	–	–	﹤0.01%	687
2018 Q4	$14K	Hold	300	–	–	﹤0.01%	676
2018 Q3	$13K	Hold	300	–	–	﹤0.01%	760
2018 Q2	$12K	Hold	300	–	–	﹤0.01%	793
2018 Q1	$22K	Hold	300	–	–	﹤0.01%	634
2017 Q4	$20K	Hold	300	–	–	﹤0.01%	666
2017 Q3	$15K	Hold	300	–	–	﹤0.01%	677
2017 Q2	$14K	Hold	300	–	–	﹤0.01%	690
2017 Q1	$11K	Hold	300	–	–	﹤0.01%	693
2016 Q4	$4K	Hold	300	–	–	﹤0.01%	792
2016 Q3	$4K	Hold	300	–	–	﹤0.01%	749
2016 Q2	$3K	Hold	300	–	–	﹤0.01%	775
2016 Q1	$5K	Hold	300	–	–	﹤0.01%	650
2015 Q4	$7K	Buy	300 +150	+100%	+$3.78K	﹤0.01%	655
2015 Q3	$4K	Buy	150 +50	+50%	+$3.14K	﹤0.01%	715
2015 Q2	$8K	Buy	+100	New	+$9.79K	﹤0.01%	674

Other funds holding ESPR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

PCM

PenderFund Capital Management Vancouver, British Columbia, Canada $639M AUM 31.05% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Trust Company of Vermont's ESPR Position: Q3 2025 in Review

Trust Company of Vermont sold out of Esperion Therapeutics (ESPR) in Q3 2025, closing a stake of 300 shares — an estimated $295 sold.

Trust Company of Vermont first reported a position in ESPR in Q2 2015 and held it in 38 quarters. The position peaked at $22K in Q1 2018. 188 funds tracked by Wall St. Rank hold ESPR as of Q3 2025.

Trust Company of Vermont reported no remaining Esperion Therapeutics position as of Q3 2025 after selling out during the quarter.
Trust Company of Vermont sold 300 Esperion Therapeutics shares in Q3 2025, an estimated $295.
Trust Company of Vermont first reported a position in Esperion Therapeutics in Q2 2015 and held it in 38 quarters.
Trust Company of Vermont's Esperion Therapeutics position peaked at $22K in Q1 2018.
188 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2025.

Based on Trust Company of Vermont's 13F filing for Q3 2025, filed 14 Oct 2025.